Stock DNA
Pharmaceuticals & Biotechnology
DKK 34,797 Million ()
5.00
NA
0.00%
-0.86
43.80%
2.29
Revenue and Profits:
Net Sales:
9,088 Million
(Quarterly Results - Jun 2025)
Net Profit:
7,574 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.56%
0%
13.56%
6 Months
8.54%
0%
8.54%
1 Year
-32.24%
0%
-32.24%
2 Years
48.59%
0%
48.59%
3 Years
141.32%
0%
141.32%
4 Years
276.34%
0%
276.34%
5 Years
121.65%
0%
121.65%
Zealand Pharma A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
97.92%
EBIT Growth (5y)
66.52%
EBIT to Interest (avg)
-66.89
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.11
Tax Ratio
0.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
2.25
EV to EBIT
2.55
EV to EBITDA
2.54
EV to Capital Employed
-28.59
EV to Sales
2.06
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
43.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
9,088.30
34.10
26,551.91%
Operating Profit (PBDIT) excl Other Income
8,519.50
-260.90
3,365.43%
Interest
9.10
14.40
-36.81%
Exceptional Items
-168.40
-37.20
-352.69%
Consolidate Net Profit
7,573.70
-292.80
2,686.65%
Operating Profit Margin (Excl OI)
936.70%
-7,842.70%
877.94%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 26,551.91% vs 227.88% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 2,686.65% vs 8.36% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
62.70
342.80
-81.71%
Operating Profit (PBDIT) excl Other Income
-1,243.20
-532.90
-133.29%
Interest
40.90
29.00
41.03%
Exceptional Items
38.60
-155.80
124.78%
Consolidate Net Profit
-1,078.80
-703.70
-53.30%
Operating Profit Margin (Excl OI)
-20,243.30%
-1,637.30%
-1,860.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -81.71% vs 229.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -53.30% vs 27.12% in Dec 2023
About Zealand Pharma A/S 
Zealand Pharma A/S
Pharmaceuticals & Biotechnology
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.
Company Coordinates 
Company Details
Sydmarken 11 , SOEBORG None : 2860
Registrar Details






